Delcath Systems reported Q2 2026 revenue of $29.1M, up from $24.2M a year earlier (+$4.9M, ~+20%), supported by continued HEPZATO KIT sales growth. Management highlighted ongoing commercial expansion and additional investment in clinical programs beyond metastatic uveal melanoma, indicating steady momentum rather than a one-off improvement.
Delcath Systems reported Q2 2026 revenue of $29.1M, up from $24.2M a year earlier (+$4.9M, ~+20%), supported by continued HEPZATO KIT sales growth. Management highlighted ongoing commercial expansion and additional investment in clinical programs beyond metastatic uveal melanoma, indicating steady momentum rather than a one-off improvement.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
